



## ASX Announcement

27 May 2025

# 2025 Annual General Meeting Results

**Melbourne, Australia, 27 May 2025** – In accordance with ASX Listing Rule 3.13.2 and section 251AA of the *Corporations Act 2001 (Cth)*, Avecho Biotechnology Limited (ASX: AVE) advises that the details of the resolutions and the proxies received in respect of each resolution at its Annual General Meeting today are set out in the attached proxy summary.

### For enquiries, please contact

Melanie Leydin  
Company Secretary  
+61 3 9692 7222

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

### About Avecho

Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's lead asset is a proprietary cannabidiol ("CBD") TPM soft-gel capsule demonstrated to increase CBD absorption. The CBD soft-gel capsule is currently undergoing Phase III clinical development for the treatment of insomnia.

See more here - [avecho.com.au](https://avecho.com.au)

**Annual General Meeting  
Tuesday 27 May 2025  
Voting Results**

The following information is provided in accordance with section 251AA(2) of *Corporations Act 2001* (Cth) and ASX Listing Rule 3.13.2.

Resolution Details				Show of Hands (S) or Poll (P)	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution		Resolution Type	If s259U applies	S or P	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain	Carried/ Not Carried
1	Adoption of Remuneration Report	Ordinary	N/A	P	189,027,735 75.00%	10,338,242 4.10%	52,650,578 20.90%	1,782,251 -	614,032,512 98.34%	10,338,242 1.66%	1,782,251 -	Carried
2	Re-Election of Dr Gregory Collier as a Director of the Company	Ordinary	N/A	P	226,618,007 79.83%	901,282 0.32%	56,328,911 19.85%	301,445 -	669,634,449 99.87%	901,282 0.13%	301,445 -	Carried
3(a)	Approval to grant Options to Dr Gregory Collier (or his nominee)	Ordinary	N/A	P	180,684,900 71.54%	17,056,277 6.75%	54,835,578 21.71%	26,572,891 -	607,874,677 97.27%	17,056,277 2.73%	40,906,223 -	Carried
3(b)	Approval to grant Options to Dr Ross Murdoch (or his nominee)	Ordinary	N/A	P	180,388,900 71.41%	19,338,969 7.65%	52,873,928 20.94%	26,547,849 -	605,617,027 96.91%	19,338,969 3.09%	40,881,181 -	Carried
3(c)	Approval to grant Options to Mr Matthew McNamara (or his nominee)	Ordinary	N/A	P	92,414,914 56.83%	17,177,319 10.56%	53,035,578 32.61%	118,188,501 -	517,804,691 96.79%	17,177,319 3.21%	132,521,833 -	Carried
3(d)	Approval to grant Options to Ms Katherine Connell (or her nominee)	Ordinary	N/A	P	174,154,900 71.35%	16,381,319 6.71%	53,565,578 21.94%	35,047,849 -	600,074,677 97.34%	16,381,319 2.66%	49,381,181 -	Carried
4	Approval of 10% Placement Facility	Special	N/A	P	124,448,535 64.94%	10,707,439 5.59%	56,474,631 29.47%	92,519,040 -	567,610,697 98.15%	10,707,439 1.85%	92,519,040 -	Carried

\*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.